drugset / Trial / NCT02131012
Intravitreal Celecoxib for Chronic Uveitis
NaSingle-groupOpen-labelTreatment
Summary
Intraocular delivery of celecoxib will be an effective means to treat inflammation and macular edema and prevent structural complications and vision loss in patients with chronic inflammation or macular edema who are unable to tolerate corticosteroids due to their side effects.
Timeline
- Start
- 2015-06
- Primary completion
- 2016-11-01
- Completion
- 2016-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Celecoxib | Other / unclassified | 1 mg | Intravitreal |
| Subject | Celecoxib | Other / unclassified | 4 mg | Intravitreal |
Indications
No indication recorded.